SIGA Technologies Inc.
-
Ticker
SIGA
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in New York City, New York
SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Their lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally
…More administered and intravenous (IV) formulation antiviral medicine for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule product of which 2 million oral courses have been delivered to the Strategic National Stockpile under Project BioShield. The FDA approved the oral formulation of TPOXX for the treatment of smallpox on July 13, 2018. In September 2018, SIGA signed a new contract with Biomedical Advanced Research and Development Authority (BARDA) for procurement of oral and intravenous formulations of TPOXX, and development activities.
SIGA Technologies Inc.
Most Recent Responsibility Report
Our service enables potential investors to review the most recent and archived SIGA Technologies Inc. Sustainability Report, SIGA Technologies Inc. Corporate Social Responsibility Report, SIGA Technologies Inc. CSR Report, SIGA Technologies Inc. Corporate Responsibility, SIGA Technologies Inc. CR Report, SIGA Technologies Inc. Citizenship Report, SIGA Technologies Inc. ESG Report, and SIGA Technologies Inc. Environmental Report online.